Edited by Eric R. Fearon TGF␤ signaling via SMAD proteins and protein kinase pathways up-or down-regulates the expression of many genes and thus affects physiological processes, such as differentiation, migration, cell cycle arrest, and apoptosis, during developmental or adult tissue homeostasis. We here report that NUAK family kinase 1 (NUAK1) and NUAK2 are two TGF␤ target genes. NUAK1/2 belong to the AMP-activated protein kinase (AMPK) family, whose members control central and protein metabolism, polarity, and overall cellular homeostasis. We found that TGF␤-mediated transcriptional induction of NUAK1 and NUAK2 requires SMAD family members 2, 3, and 4 (SMAD2/3/4) and mitogen-activated protein kinase (MAPK) activities, which provided immediate and early signals for the transient expression of these two kinases. Genomic mapping identified an enhancer element within the first intron of the NUAK2 gene that can recruit SMAD proteins, which, when cloned, could confer induction by TGF␤. Furthermore, NUAK2 formed protein complexes with SMAD3 and the TGF␤ type I receptor. Functionally, NUAK1 suppressed and NUAK2 induced TGF␤ signaling. This was evident during TGF␤-induced epithelial cytostasis, mesenchymal differentiation, and myofibroblast contractility, in which NUAK1 or NUAK2 silencing enhanced or inhibited these responses, respectively. In conclusion, we have identified a bifurcating loop during TGF␤ signaling, whereby transcriptional induction of NUAK1 serves as a negative checkpoint and NUAK2 induction positively contributes to signaling and terminal differentiation responses to TGF␤ activity.
transcriptionally induced, whereas others can be regulated by allosteric cofactors, such as AMP, or by ubiquitination (12) . The prototype AMPKs phosphorylate the tuberous sclerosis complex 2 protein and inhibit the mammalian target of rapamycin (mTOR) complex 1 kinase, suppressing mRNA translation and cell proliferation (10, 13) .
Influenced from the evidence on SIK acting downstream of TGF␤ signaling (7) (8) (9) , we performed a screen of all AMPKs expressed in two TGF␤-responsive cell models, a mouse mammary epithelial cell and a human skin fibroblast, and found that Nuak1/NUAK1 and Nuak2/NUAK2 mRNAs are induced in response to TGF␤. The novel (nua) kinase (NUAK) subfamily consists of two members, NUAK1 or AMPK-related kinase 5 (ARK5) and NUAK2 or sucrose nonfermenting AMPK-related kinase (SNARK). NUAK2 can be transcriptionally induced by UV light (14) and is activated under DNA damage; oxidative, glucose, or glutamine deprivation stress; and high AMP or low ATP levels (15) . NUAK2 can be induced during muscle differentiation, protecting myocytes from undergoing apoptosis (16) . NUAK2 regulates the myosin regulatory light chain (MLC) phosphatase via myosin-phosphatase Rho-interacting protein (17) . NUAK2 phosphorylates and inhibits MYPT1, the regulatory subunit of MLC phosphatase, stabilizing actin filaments and mediating contraction of smooth muscle cells (17) .
Pathologically, NUAK2 regulates hepatitis C virus replication and enhances TGF␤ signaling and hepatic fibrosis (18) . In melanomas, NUAK2 affects cell cycle progression and migration (19, 20) , whereas it affects gene expression in human cervical cancer cells under stress (21) . Tumor necrosis factor ␣ and CD95 induce NUAK2 expression in breast cancer cells to promote invasiveness and survival (22) . NUAK1 physically interacts with MYPT1 and phosphorylates and inhibits its phosphatase activity, enhancing phosphorylation of MLC2 (23) . NUAK1 contains a predicted AKT phosphorylation motif, which, when phosphorylated, results in elevated phosphorylation of the ataxia-telangiectasia protein and of p53, promoting survival (24) . Accordingly, NUAK1 suppresses apoptosis induced by nutrient starvation and death receptors in hepatoma cells (24) . NUAK1 can also modulate AMPK activity and therefore ATP levels in Myc-driven tumors, by limiting mTOR signaling. NUAK1 depletion released proapoptotic signals both in vitro and in vivo in hepatocellular carcinoma (25) , establishing NUAK1 as a survival factor for tumor cells. Furthermore, NUAK1 can activate the polo kinase-1 indirectly, via inhibition of protein phosphatase 1␤, thus stimulating cell cycle progression through the S phase (26) . Moreover, elevated NUAK1 levels can drive invasion of pancreatic cancer or exert tumor-promoting effects in breast cancer (27, 28) . On the other hand, NUAK1 can be anti-tumorigenic, by binding and phosphorylating p53 in a LKB1 activation-dependent manner, by inducing expression of the cell cycle inhibitor p21 and G 1 /S phase arrest (29) . In normal diploid fibroblasts, NUAK1 is induced upon aging, mediating senescence (30) , further supporting a tumor-suppressing function.
The present study ascribes novel functions to NUAK1 and NUAK2. Transcriptional induction of NUAK1 and NUAK2 by TGF␤ generates signaling loops in a way that NUAK1 inhibits, whereas NUAK2 promotes, biological responses mediated by TGF␤ signaling.
Results

TGF␤ transcriptionally induces Nuak1/NUAK1 and Nuak2/ NUAK2 in a SMAD-and kinase-dependent manner
By screening for expression of 15 AMPK members and related kinases in human foreskin AG1523 fibroblasts and in mouse mammary epithelial NMuMG cells that respond well to TGF␤, we found that many AMPKs were expressed in both cell types, whereas some kinases were essentially undetectable ( Fig.  1 (A and B) ; data not shown). We asked whether TGF␤ could induce expression of these kinases and found that NUAK1, NUAK2, and SIK1 were reproducibly induced by 2-fold or more in the fibroblasts (Fig. 1A) ; Nuak2 mRNA was induced by about 2-fold in mammary cells (Fig. 1B) . TGF␤-dependent inducibility was reproduced in diverse cell types, including mouse C2C12 myoblasts and LKB1 knockout MEFs (data not shown), immortalized human mammary epithelial MCF10A cells and their Ras-transformed derivatives (MCF10A-Ras MII), immortalized human keratinocytes HaCaT, and human lung adenocarcinoma A549 cells (Fig. S1 ). The degree of inducibility of NUAK1 mRNA, however, varied between cell types (Fig. S1A ). Protein analysis confirmed that NUAK1 and NUAK2 were induced in a time-dependent manner in human fibroblasts (Fig.  1C ), mammary cells (data shown for NUAK2 only; Fig. 1D ), and HaCaT and human cervical carcinoma HeLa cells (Fig. S1B ). Protein specificity was confirmed by predicted electrophoretic mobility, inducibility by TGF␤ stimulation, and loss of protein upon transfection of cells with siRNAs ( Fig. 1D, Nuak2) .
After blocking ribosomal function with cycloheximide, TGF␤ induced NUAK1 mRNA by about 7-fold in AG1523 cells ( Fig. 2A) and Nuak2 mRNA by about 4-fold in the NMuMG cells ( Fig. 2B) ; these were comparable -fold inductions relative to control without cycloheximide (Fig. 2, A and B) , indicating that TGF␤ regulates NUAK1 and Nuak2 expression at the transcriptional level. Translational inhibition resulted in accumulation of NUAK1 and Nuak2 mRNA in the absence of TGF␤ (Fig.  2, A and B) ; NUAK1 or Nuak2 protein levels were markedly increased in the presence of TGF␤ but disappeared after cycloheximide treatment, as expected (Fig. 2, A and B) . SMAD2 phosphorylation, which verified active TGF␤ signaling, was not influenced by cycloheximide, because T␤RI phosphorylates a pre-existing pool of SMAD2 (Fig. 2, A and B) .
Actinomycin D, which inhibits transcription, blocked TGF␤induced Nuak2 mRNA expression ( Fig. 2C) , supporting a transcriptional mechanism. Depletion of SMAD4 in AG1523 fibroblasts using transient siRNA transfection, blocked induction of NUAK1 protein by TGF␤ ( Fig. 2D ), suggesting that TGF␤ can enhance NUAK1 expression via a SMAD4-dependent pathway. Depleting Smad4 mRNA in NMuMG cells blocked the induction of both Nuak2 and Gadd45␥ mRNAs by TGF␤ ( Fig. 2E) ; Gadd45␥ is a known TGF␤-inducible gene (31) used as positive control. In SMAD4-null human breast carcinoma MDA-MB-468 cells, NUAK2 protein expression and weak inducibility by TGF␤ were rescued upon reconstitution of SMAD4 in the cells (Fig. 2F ). Inhibiting T␤RI kinase activity with two independent
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chemical inhibitors (LY2157299 and SB505124) completely suppressed TGF␤-induced NUAK1 and NUAK2 levels in AG1523 cells ( Fig. 2G ). On the other hand, inhibiting MAPK ERK1/2 and p38 pathways with the inhibitors Cl-1040 (PD184352, MEK inhibitor) and SB203580, respectively, significantly but not completely blocked the inducibility of Nuak2 by TGF␤ in NMuMG cells ( Fig. 2H ). Thus, TGF␤ enhances NUAK1 and NUAK2 expression in a T␤RIand SMAD4-dependent manner, with additional contributions by the MAPKs in the case of NUAK2.
Earlier genome-wide ChIP-Seq analysis (32) identified a SMAD2/3-binding region in the first NUAK2 intron in HaCaT keratinocytes, and we could identify the homologous binding region in the mouse Nuak2 gene as well ( Fig. 3A) . ChIP-qPCR analysis showed that TGF␤ stimulation for 1 h potently induced SMAD2/3 binding to the Nuak2 intronic enhancer region ( Fig.  4B ). SMAD2/3 binding to the plasminogen activator inhibitor 1 (Pai1) promoter and the hemoglobin B (Hbb) control promoter were included as positive and negative controls of the ChIP assay, respectively ( Fig. 3B ). We consider the weak TGF␤-induced binding of SMAD2/3 to the Hbb region as background nonspecific binding ( Fig. 3B ). Inspecting the promoter sequence up to 2 kbp upstream from the transcriptional start site (TSS), we could not identify any specific SMAD2/3 binding using ChIP (data not shown). We therefore cloned the mouse Nuak2 intronic enhancer region into a luciferase construct containing a minimal promoter ( Fig. 3C ). Sustained TGF␤ signaling due to transfection of a constitutively active T␤RI (ALK5TD) resulted in an increase of luciferase activity compared with control ( Fig. 3D ), suggesting that the Nuak2 intronic region has the potential to function as a TGF␤inducible enhancer. Transfection of the same enhancer construct into NMuMG cells showed that TGF␤ signaling enhanced its already high basal activity ( Fig. 3E ). Cloning of 1-or 2-kbp promoter regions of mouse Nuak2 into luciferase constructs ( Fig. 3C ) did not yield any positive regulation by TGF␤ ( Fig. 3E ), in agreement with the scan of the promoter region for the SMAD2/3binding region via ChIP analysis. Thus, TGF␤ signaling promotes NUAK2 transcription minimally via a SMAD protein complex with and without TGF␤ (5 ng/ml) stimulation for 24 h and normalized to Gapdh. C, immunoblot analysis of NUAK1 and NUAK2 in AG1523 cells at the indicated time periods of TGF␤ (1 ng/ml) stimulation. Phospho-SMAD2 and phospho-SMAD3 serve as positive controls for TGF␤ activity. ␣-Tubulin serves as a protein-loading control. Molecular size markers in kDa are shown. D, imunoblotting for NUAK2, phospho-SMAD2, and total p38 levels in NMuMG cells after adding fresh medium containing TGF␤ (5 ng/ml) for 1 h. Total p38 MAPK serves as a protein-loading control. A star shows nonspecific protein bands. Molecular size markers in kDa are shown. All bar graphs show average values derived from triplicate determinations and the corresponding S.D. values. Graphs show mean Ϯ S.E. (error bars) from at least three independent experiments. *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001; statistically significant compared with the non-TGF␤-treated samples.
that associates with an enhancer in the first NUAK2 intron. Whether a similar enhancer mediates inducibility of NUAK1 to TGF␤ remains to be examined.
NUAK2 associates with SMAD3 and T␤RI
A previous high-throughput screen for proteins that interact with TGF␤ receptors or SMADs identified binding of NUAK2 (20 M) or an equivalent volume of PBS as negative control for 1 h followed by TGF␤ (1 ng/ml) stimulation for 5 h. On the right, corresponding immunoblot for NUAK1, phospho-SMAD2 and total SMAD2 under the conditions used in the samples for real-time qRT-PCR. Molecular size markers in kDa are shown. One representative experiment of two is shown. B, real-time qRT-PCR analysis of Nuak2 mRNA normalized to Gapdh mRNA from NMuMG cells after treatment with vehicle or cycloheximide for 15 min followed by TGF␤ (5 ng/ml) stimulation for 1 h. Immunoblots of NUAK2, phospho-SMAD2, and total SMAD2 proteins serve as controls for the RNA analysis. SMAD2 serves as a protein-loading control. Molecular size markers in kDa are shown. C, NMuMG cells were pretreated with vehicle or actinomycin D for 1 h before treatment with TGF␤ (5 ng/ml) for 1 h. Nuak2 mRNA was normalized to Gapdh mRNA as measured by real-time qRT-PCR. D, immunoblotting of NUAK1 and SMAD4. AG1523 cells were stimulated with TGF␤ (1 ng/ml) for 5 h. Ponceau-S staining of the immunoblot serves as a protein-loading control. Molecular size markers in kDa are shown. E, mRNA expression of Nuak2, Gadd45␥, and Smad4 in NMuMG cells after treatment with control or Smad4 siRNA and TGF␤ (5 ng/ml) stimulation for 1 h. F, immunoblots of NUAK2, PAI-1, SMAD4, and ␤-actin proteins in MDA-MB-468 cells transiently infected with Adex-LacZ or Adex-SMAD4 (the latter at two different multiplicities of infection, 1 and 4) prior to cell starvation and stimulation with TGF␤ (5 ng/ml) for 24 h. ␤-Actin serves as protein-loading control; a star shows nonspecific protein bands. Molecular size markers in kDa are shown. G, immunoblotting of NUAK1 and NUAK2 in AG1523 cells after treatment with TGF␤ (5 ng/ml) for 3 h in the presence of T␤RI kinase inhibitors LY2157299 (5 M) or SB505124 (2.5 M) or DMSO (0.1%). Molecular size markers in kDa are shown. H, immunoblots of NUAK2, phospho-ERK1/2, phospho-SMAD2, phospho-SMAD3, SMAD4, and ␤-actin proteins in NMuMG cells serum-starved overnight, followed by pretreatment with the indicated inhibitors or vehicle (DMSO) for 1 h prior to stimulation with TGF␤ (1 ng/ml) for 6 h. ␤-Actin serves as protein-loading control. Molecular size markers in kDa are shown. Data are presented as mean Ϯ S.E. (error bars) after performing at least three independent experiments. Asterisks imply significant differences compared with controls: *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001.
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to T␤RI (33) . Influenced by these results, we examined this possibility thoroughly. After co-expression of GST-NUAK2 together with FLAG-tagged SMAD2, SMAD3, or SMAD4, we observed strong complex formation between NUAK2 and SMAD3 and much weaker complex between NUAK2 and SMAD2 ( Fig. 4A ). GST-NUAK2 associated with endogenous SMAD3 when the cells were stimulated with TGF␤, whereas treatment with a potent T␤RI kinase inhibitor (GW6604) resulted in weak, basal protein association ( Fig. 4B ). Probing for the GST tag of NUAK2 did not reveal any association between GST and SMAD3 ( Fig. 4B ).
SMAD3 is a modular protein composed of an N-terminal Mad homology 1 (MH1) domain that binds to DNA, contains a nuclear localization signal, and associates with transcription factors; a middle linker domain that is phosphorylated and ubiquitinated and regulates protein conformation and stability; and a C-terminal MH2 domain that becomes phosphorylated by T␤RI in its very C-terminal diserine motif and interacts with transcription factors, performing a transcriptional activation function (2, 4, 6) . Using deletion mutants of SMAD3, we could demonstrate that GST-NUAK2 formed complexes with the linker and MH2 domains of SMAD3, but not with the MH1 domain ( Fig. 4C ). Deletion mutants spanning the linker and MH2 domains and full-length SMAD3 protein resulted in much weaker protein complexes ( Fig. 4C ), suggesting that an exposed MH2 domain (possibly after C-terminal phosphoryla-tion by T␤RI) presents the highest affinity for NUAK2. At the endogenous level, association between Nuak2 and Smad3 could be demonstrated in mouse NMuMG ( Fig. 4D ) and between NUAK2 and SMAD3 in human HaCaT cells ( Fig. 4E ). In all cases, the association between endogenous proteins was exclusively TGF␤-dependent ( Fig. 4 , D and E).
Using the same approach, we could also demonstrate that GST-NUAK2 forms complexes with T␤RI, and this association did not change significantly after a brief stimulation of the cells with TGF␤ ( Fig. 5A ). Control immunoglobulin or Sepharose beads generated clean background without nonspecific interactions ( Fig. 5A ). All of the above results confirm and significantly extend the original high-throughput findings (33) and provide evidence for complex formation between NUAK2 and two major components of TGF␤ signaling, T␤RI and SMAD3 ( Fig. 5B ).
NUAK1 and NUAK2 differentially regulate matrix gene responses to TGF␤ signaling
To assess the function of NUAK1 and NUAK2 induction in response to TGF␤ signaling, and influenced by the ability of NUAK2 to associate with SMAD3 and T␤RI, we knocked down NUAK2 using siRNA in the AG1523 fibroblasts and examined first the potency of regulation of established TGF␤-induced genes, such as the extracellular matrix genes SERPINE 1 (plasminogen activator inhibitor 1, PAI1), fibronectin 1 (FN1), and Shown is a schematic diagram of the mouse Nuak2 gene spanning the promoter sequences, the transcriptional start site (TSS), the first exon, and part of the first intronic sequence. B, ChIP assays using an antibody against endogenous SMAD2/SMAD3 (S2/3) and amplification of genomic sequences corresponding to the Nuak2 intronic enhancer, the Pai1 promoter, and the ␤-globin (Hbb) control region in NMuMG cells stimulated with or without 5 ng/ml TGF␤ for 1 h. Control immunoprecipitations with mouse IgG are also shown as reference. The amount of PCR-amplified DNA signal after ChIP is normalized against the equivalent PCR signal of the input chromatin prior to immunoprecipitation, and the relative ratios are shown in the diagrams as average values determined from triplicate determinations with their corresponding S.E. (error bars). C, the genomic fragments, depicted in A, that were cloned into the luciferase reporter are shown relative to the luciferase (luc) cDNA in the corresponding constructs. D, luciferase assay from HEK 293T cells transiently transfected with the Nuak2 enhancer construct and pcDNA3 control or constitutively active pcDNA3-ALK5TD. E, luciferase assay was performed using NMuMG cells transiently transfected with the Nuak2 1-or 2-kbp promoters and the Nuak2 intronic enhancer constructs with or without TGF␤ (5 ng/ml) stimulation for 17 h. Each independent experiment was repeated at least three times. Asterisks depict differences compared with respective controls or between the conditions indicated with lines: *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001.
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TIMP metallopeptidase inhibitor 1 (TIMP1; Fig. 6A ). TGF␤ induced FN1, SERPINE1, and TIMP1 levels in a time-dependent manner; however, knockdown of NUAK2 reduced the potency of induction of these genes by TGF␤ ( Fig. 6A ). FN protein expression analysis gave similar results, especially at late time points, when the levels of endogenous NUAK2 induced by TGF␤ in control cells were high (Fig. 6B ). The same result was corroborated in HaCaT keratinocytes, where two individual and distinct siRNAs targeting human NUAK2 effectively reduced the inducibility of FN by TGF␤ (Fig. 6C ). The two distinct and single siRNA oligonucleotides verified that the results obtained based on siRNA pools used in the previous experiments ( Fig. 6, A and B) were not prone to off-target effects. To bypass even more the possibility of off-target effects, we analyzed FN protein expression in mouse NMuMG cells after transfection of individual siRNAs targeting mouse Nuak2 and confirmed again the positive role of endogenous Nuak2 on FN inducibility by TGF␤ ( Fig. 6D ).
Unexpectedly, control experiments, where the steady-state levels of SMAD proteins were monitored, revealed that silencing of NUAK2 in AG1523 fibroblasts had a strong impact on the level of SMAD3, but not of SMAD4 ( Fig. 6B ), suggesting that the interaction between NUAK2 and SMAD3 ( Fig. 4 ) may play a positive role in preserving SMAD3 protein stability. Repeat-ing this experiment with the two individual siRNAs in the fibroblasts corroborated the observations and confirmed down-regulation of phosphorylated and of total SMAD3 levels upon NUAK2 depletion (Fig. 6B ). The same result was further consolidated in mouse NMuMG cells using an additional and distinct siRNA (Fig. 6D ). These results suggested that TGF␤-induced NUAK2 may function as a positive regulator of sustained (long-term) TGF␤ signaling responses. Under the above conditions, NUAK1 silencing in HaCaT cells enhanced the response of endogenous FN to TGF␤ stimulation ( Fig. 6E ), exhibiting an opposite phenotype compared with the NUAK2 knockdown ( Fig. 6C ) in the same cells.
Finally, to provide more direct evidence for the negative (NUAK1) or positive (NUAK2) role that these two kinases play in TGF␤ signaling, we employed a luciferase reporter construct that is sensitive to the transcriptional activity of the SMAD3/SMAD4 complex, CAGA 12 -luc ( Fig. 6 , F and G). Transient expression of exogenous NUAK1 in HEK 293T cells suppressed the CAGA 12 -luc transcriptional response to TGF␤ ( Fig. 6F ), whereas transient expression of NUAK2 in the same cells strongly enhanced the promoter response ( Fig. 6G ), suggesting that the two protein kinases have an impact on the transcriptional activity of the SMAD3/4 complex. These data therefore support a role of NUAK1 as a Figure 4 . NUAK2 physically interacts with SMAD3. A, HEK 293T cells were co-transfected with FLAG-tagged SMAD2 (S2), SMAD3 (S3), or SMAD4 (S4) or the respective empty vector and GST-tagged NUAK2 or GST alone (0.5 g of DNA/plasmid). After treatment with TGF␤ (2.5 ng/ml) for 2.5 h, cell lysates were immunoprecipitated (IP) using FLAG-embedded agarose beads for 1 h, and proteins were eluted and subjected to SDS-PAGE. The corresponding whole-cell lysates (WCL; 2.5% of input used for immunoprecipitation) were analyzed in parallel. Proteins were detected by using NUAK2, FLAG, and GST antibodies. The immunoglobulin light chain (LC) is also marked. IB, immunoblotting. B, GST-tagged NUAK2 or GST alone was transiently transfected (1 g of DNA/plasmid) in HEK 293T cells. Following either stimulation of cells with TGF␤ (2 ng/ml) for 30 min or T␤RI inhibitor GW6604 (3 M) for 1 h to quench autocrine signaling, cell lysates were incubated overnight with SMAD3 antibody (0.5 g) or its respective rabbit isotype (0.5 g) as a negative control, followed by pulldown by protein A Dynabeads for 1 h. Immunoprecipitated proteins were eluted and resolved by SDS-PAGE, followed by immunoblotting for SMAD3, NUAK2, and GST. The anti-SMAD3 antibody never pulled down transfected GST alone but did immunoprecipitate GST-NUAK2 protein. Note that the protein band detected in the SMAD3 immunoprecipitation corresponds to the light chain of the anti-SMAD3 immunoglobulin (marked on the left of the immunoblot), which migrates slightly faster than the GST protein band shown in the first lane of the WCL. C, Myc-tagged domains of SMAD3 (MH1, MH2, linker (L), full-length (FL), MH1-L, and L-MH2) or Myc-tagged empty vector were co-transfected with GST-NUAK2 or GST alone (0.5 g/DNA plasmid). After 1 day, cells were starved overnight with 2% FBS/DMEM, and the second day post-transfection, they were treated with TGF␤ (2 ng/ml) for 2.5 h. Thereafter, cell lysates were immunoprecipitated with Myc-embedded agarose beads for 1 h. The samples were resolved by SDS-PAGE in parallel with their respective WCL, and proteins were identified by utilizing NUAK2, Myc, and GST antibodies. The immunoglobulin light chain is also marked. Note that the middle and bottom immunoblots are one and the same; the bottom is an exact duplication of part of the middle immunoblots that are exposed slightly longer to emphasize the lack of GST protein on the immunoprecipitation (left part) and its presence on the WCL (right part). D, NMuMG cells were treated with TGF␤ (5 ng/ml) for 2 h, and then following immunoprecipitation with Smad3 or control antiserum, eluents together with WCL were resolved by SDS-PAGE, followed by Nuak2, Smad3, and pSmad3 immunoblotting. E, as in D, HaCaT cells were stimulated with TGF␤ (5 ng/ml) for 2 h, and the cell lysates were incubated with SMAD3 antibody or control IgG overnight. Immunoprecipitated proteins were separated by SDS-PAGE, and NUAK2, SMAD3, and pSMAD3 were detected via immunoblotting. Molecular size markers in kDa are shown in every immunoblot. A, GST-tagged NUAK2 or the respective empty vector was transiently transfected (1 g of plasmid DNA in total) in HEK 293T cells. After incubation with TGF␤ (2 ng/ml) for 30 min, cell lysates were incubated with T␤RI antibody (2 g), rabbit IgG (2 g), or beads overnight, followed by incubation with protein A Dynabeads for 1 h. After washes, proteins were resolved by SDS-PAGE, and NUAK2, T␤RI, or GST was detected by immunoblotting. WCL samples were analyzed concurrently. Molecular size markers in kDa are shown. IP, immunoprecipitation. B, diagram of physical interactions between NUAK2 and SMAD3 or T␤RI. Shown is a schematic representation of SMAD3 domains containing the MH1, linker, and MH2 regions and a schematic representation of NUAK2 with Thr 208 required for activation of protein kinase activity portrayed at the T loop in the N-terminal kinase domain, as well as the central ubiquitin-associated domain (UBA). The T␤RI domains, extracellular (ECD), transmembrane (TMD), and juxtamembrane (JMD), containing the GS motif being phosphorylated by T␤RII, and kinase, are depicted. N and C, the respective N and C termini of each protein. Brackets indicate domains that interact. Figure 6 . NUAK1 and NUAK2 regulate TGF␤ signaling. A, relative mRNA levels of SERPINE1, FN1 (fibronectin 1), and TIMP1 were analyzed by real-time qRT-PCR. Values were normalized to GAPDH and are shown as -fold difference. AG1523 cells transfected with scrambled siRNA or siRNA targeting NUAK2 were starved overnight in 0.01% FBS/DMEM and incubated with TGF␤ (5 ng/ml) for different time periods. B, as in A, AG1523 cells post-siRNA transfection were starved and treated with TGF␤ (5 ng/ml) for the indicated time periods. Samples were analyzed by immunoblotting for FN, NUAK2, SMAD3, SMAD4, and ␣-tubulin, used as a loading control. On the right, immunoblot analysis for NUAK2, pSMAD3, and SMAD3 was performed after transfecting AG1523 with two different siRNAs (#2 and #4) targeting NUAK2. ␣-Tubulin and Ponceau-S staining serve as loading controls. A star shows nonspecific protein bands. Molecular size markers in kDa are shown. C, HaCaT cells transfected with control or two distinct NUAK2 siRNAs (#2 and #4) were either starved with 2% FBS/DMEM overnight and thereafter stimulated with TGF␤ (5 ng/ml) for 24 h or treated directly with TGF␤ (5 ng/ml) for 2 days. Samples were analyzed by immunoblotting for FN and NUAK2. Ponceau-S staining serves as a loading control. A star shows nonspecific protein bands. Molecular size markers in kDa are shown. D, NMUMG cells were subjected to transfection with scrambled siRNA or siRNA against Nuak2 (mm #3); thereafter, they were stimulated with or without TGF␤ (5 ng/ml) for 24 h, and immunoblot analysis against Nuak2, Fn, Smad3, and ␣-tubulin (␣-Tub) was performed. Molecular size markers in kDa are shown. Dotted lines mark the removal of intermediate samples from the immunoblot. E, HaCaT cells transfected with scrambled siRNA or siRNA targeting NUAK1, were starved overnight in 2% FBS/DMEM. Three days after the first transfection, cells were treated with TGF␤ (1 ng/ml) for 24 h. Respective immunoblotting of FN and NUAK1 proteins is depicted, and Ponceau-S (Ponc-S) staining served as loading control. Molecular size markers in kDa are shown. F, luciferase assay in HEK 293T cells that were transfected with CAGA 12 -luc and ␤-gal reporters together with the indicated expression vectors; 1 day post-transfection, cells were starved overnight in 2% FBS/DMEM and were subjected to TGF␤ stimulation (1 ng/ml) for 24 h. Luciferase activity was measured and normalized to ␤-gal. Values are depicted as -fold difference. All graph bars are shown as average Ϯ S.E. (error bars) based on at least three independent experiments. Asterisks illustrate significant differences between the conditions indicated and respective control: *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001.
negative mediator, and of NUAK2 as a positive mediator, of TGF␤ signals.
Regulation of cytostatic and epithelial-mesenchymal transition (EMT) responses by NUAK kinases
Another well-established TGF␤-mediated physiological response is the cell cycle arrest of epithelial cells, and NMuMG epithelial cells and HaCaT keratinocytes have been valuable cell models in such studies (6) . We first used the NMuMG-Fucci cell model that tracks the phases of the cell cycle based on accumulation of fluorescent probes (GFP mAG fused to geminin generates green color in the nuclei of cells during S/M/G 2 phases, and red fluorescent protein mKO2 fused to Cdt1 generates red color in the nuclei of cells during the G 1 /G 0 phases (7, 9) ). TGF␤ stimulation for 24 h arrested most of the cells (75-80%) in G 1 (red nuclei; Fig. 7A ). Silencing Nuak2 with two independent siRNAs significantly suppressed the TGF␤-dependent cell cycle arrest (Fig. 7A) . As a verification of the above results, thymidine incorporation assays in parental NMuMG cells, where TGF␤ suppresses incorporation up to 90%, revealed that silencing Nuak2 with the same individual mouse siRNAs significantly suppressed the TGF␤-induced growth arrest (Fig. 7B ). We then verified the impact of NUAK1 by testing human HaCaT cells. TGF␤ stimulation significantly reduced the number of HaCaT cells, which actively incorporated thymidine (S-phase cells), and correspondingly, the number of cell cycle arrested cells was measurable (30 -35%, Fig. S2 ). Silencing NUAK1 with an siRNA pool doubled the number of cell cyclearrested cells (Fig. S2) , and silencing with an independent individual siRNA had a comparable effect (Fig. 7C ), confirming that NUAK1 plays a negative role by limiting one of the most characteristic physiological responses to TGF␤. Because key mediators of the cytostatic response to TGF␤ are cyclin-dependent kinase inhibitors, such as p15 (CDKN2B), we also assessed p15 mRNA expression in NMuMG cells; as expected, TGF␤-induced p15 mRNA levels were strongly suppressed upon Nuak2 silencing (Fig. 7D) .
We then continued the analysis of EMT, a biologically important response of epithelial cells to TGF␤ (1, 6) . NMuMG cells are an excellent model for this response (6) , and silencing of endogenous Nuak2 by two independent siRNAs blocked the EMT, assessed microscopically as the loss of tight junctions (ZO-1 protein loss) and the strong gain of intra-and extracellular fibronectin deposition (Fig. 7E) , two hallmark molecular attributes of the EMT (6) . Silencing efficiency of Nuak2 in NMuMG cells was assessed during the EMT assays ( Fig. 7F ) along with mRNA analysis of additional EMT markers, including Fn1 (fibronectin 1) mRNA along with two major pro-EMT transcription factors, Zeb1 and Zeb2 (Fig. 7G ). Once again, Nuak2 contributed positively to the TGF␤-mediated induction of mRNA levels for all three genes (Fig. 7G) . Thus, the regulation of NUAK kinases seems to regulate multiple physiological responses to TGF␤.
Mesenchymal cell responses to TGF␤ are differentially regulated by NUAK1 and NUAK2
The previous biological assays were all based on epithelial cells. We then shifted our attention to mesenchymal cell responses (34) . Fibroblasts respond potently to TGF␤ and synthesize a new contractile cytoskeletal machinery characterized by ␣-smooth muscle actin (␣SMA) and associated proteins, including calponin and SM22␣ (34) . Silencing endogenous NUAK1 in the AG1523 fibroblasts induced ␣SMA and calponin, roughly to the same extent as TGF␤ stimulation for 24 h (Fig. 8A ). Silencing of NUAK1 combined with TGF␤ stimulation enhanced the ␣SMA and calponin protein responses even further (Fig. 8A) . In the same cell model, NUAK2 exhibited the inverse behavior, as expected from all previous results. Silencing endogenous NUAK2 in the fibroblasts reduced the inducibility of ␣SMA and calponin by TGF␤ and also reduced the steady-state levels of SMAD3 (Fig. 8B) .
These results were also evident after immunofluorescence microscopy of the fibroblasts, whereby intense ␣SMA-positive microfilaments could be observed upon TGF␤ stimulation in the presence of NUAK1 silencing using two independent siRNAs (Fig. 8C) . The strong ␣SMA microfilament network induced by TGF␤ became unstable and fragmented after NUAK2 silencing using two additional and distinct siRNAs ( Fig. 8C ). Contraction of extracellular collagen type I gels by differentiating myofibroblasts could be measured in response to TGF␤; NUAK1 silencing using the individually validated siRNAs enhanced basal and TGF␤-induced gel contractility (Fig. 8D ). On the other hand, when NUAK2 levels were significantly reduced by independent siRNAs, there was reduced basal and TGF␤-induced gel contractility (Fig. 8D ). Gene expression analysis after endogenous NUAK2 silencing with the independent siRNAs revealed that calponin, ACTA2/ ␣SMA, and SM22␣ mRNA levels were decreased upon NUAK2 silencing (Fig. 8E) . Thus, the NUAKs provide signals that balance the ability of fibroblasts to differentiate to contractile myofibroblasts in response to TGF␤.
Another mesenchymal cell model that we examined was mouse C2C12 myoblasts that can differentiate to myotubes upon starvation in vitro, a differentiation process potently blocked by TGF␤ signaling (35) . Previous studies have established myosin heavy chain (myosin HC) and the transcription factor myogenin as key target genes of TGF␤/Smad3 signaling in these myoblasts (35) . Both myosin HC and myogenin levels were induced upon C2C12 differentiation, and TGF␤ signaling suppressed this response (Fig. S3 ). Silencing endogenous Nuak1 by individual siRNAs enhanced the suppressive response, whereas Nuak2 silencing exhibited a partial but significant resistance to myosin HC and myogenin down-regulation by TGF␤ (Fig. S3 ). In summary, the above results establish the two sister kinases as potent negative (NUAK1) and positive (NUAK2) contributors of TGF␤ signaling in at least two mesenchymal differentiation models.
Discussion
In this paper, we demonstrate that TGF␤ signaling induces NUAK1 and NUAK2 transcription via SMAD and MAPK activity ( Figs. 1-3 ). NUAK2 protein interacts with SMAD3 and T␤RI ( Figs. 4 and 5 ), suggesting a possible role in controlling the output of TGF␤ signaling. Indeed, mainly silencing, but also experiments where NUAK1 and NUAK2 were overexpressed in various cell types, established that NUAK1 is a negative
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mediator of TGF␤ signaling, whereas NUAK2 positively contributes to the signal transduction by this cytokine (Figs. 5-7) . The functions of the two NUAK kinases seem to affect basic TGF␤ signaling, as multiple epithelial and mesenchymal cell responses are impacted by genetic perturbation of these kinases ( Figs. 6 -8 ). The impact of each NUAK kinase in differentiating
myofibroblasts establishes NUAK1 as an anti-fibrotic factor and NUAK2 as a pro-fibrotic factor (Fig. 8) . These data propose that the transcriptional induction of the two NUAK proteins generates two signaling branches, one negative and another positive.
NUAK1 and NUAK2, together with SIK (7, 9) , are members of the AMPK family of kinases, whose expression is directly regulated by TGF␤ signaling. Each of these kinases participates in different molecular processes; SIK negatively regulates TGF␤ receptor signaling, whereas NUAK1 and NUAK2 regulate SMAD transcriptional activity and SMAD3 protein levels. Interestingly, these kinases also require activation by their upstream regulator LKB1, and furthermore, LKB1 provides feedback regulation to TGF␤ signaling, by phosphorylating SMAD4 (36) . This highlights an intimate cross-talk between TGF␤, LKB1, and specific AMPKs, which is exemplified by studies in LKB1 knockout mice; LKB1 loss leads to ineffective synthesis and secretion of TGF␤ ligands, thus leading to the development of hamartomatous polyps, a hallmark of the human genetic syndrome Peutz-Jeghers, which predisposes to intestinal cancer development (37) .
The transcriptional induction of NUAK1 and NUAK2 by TGF␤ is direct and involves SMAD and MAPK activities; in the case of NUAK2, an enhancer sequence resides in the first intron of the gene, which binds the SMAD complex and, upon molecular cloning, confers inducibility to TGF␤ (Fig. 3) . Whether a similar enhancer sequence resides in the vicinity of the NUAK1 gene remains to be explored. Because SMAD complexes associate with chromatin via interaction with DNA and sequencespecific transcription factors, transcriptional regulation of NUAK1 and NUAK2 probably depends on additional SMADinteracting cofactors that remain to be elucidated and that possibly receive inputs by TGF␤-induced MAPKs.
The transcriptional induction of NUAK2 by TGF␤ is further linked to the ability of the protein kinase to form physical associations with SMAD3 and the T␤RI (Figs. 4 and 5). These results nicely confirm earlier high-throughput findings using the LUMIER proteomic platform for the identification of proteins interacting with TGF␤ receptors and SMAD proteins (33) . Our findings establish firmly this interaction using complementary biochemical assays and further map the interaction between the MH2 domain of SMAD3 and NUAK2 (Fig. 4C ). The fact that NUAK2 interacts with T␤RI and one of its immediate substrates, SMAD3, generates the hypothesis that NUAK2 may promote the interaction between T␤RI and SMAD3, facilitating its C-terminal phosphorylation by T␤RI. This raises the possibility that NUAK2 might phosphorylate either T␤RI or SMAD3. Attempts to test this hypothesis by in vitro phosphorylation assays did not give positive results (data not shown).
Silencing endogenous NUAK2 significantly down-regulated SMAD3 protein levels in various cell types (Fig. 6 ). It is possible that NUAK2 stabilizes SMAD3, thus mediating a positive role during TGF␤ signaling (see below). Furthermore, interaction assays similar to those performed for NUAK2 (Figs. 4 and 5) failed to demonstrate an association between NUAK1 and SMAD3 or T␤RI (data not shown). Despite the above caveat, all functional experiments so far converge on a model whereby NUAK1 and NUAK2 significantly regulate the output of TGF␤ signaling ( Figs. 6 -8 ). The impact of NUAK2 on TGF␤ signaling agrees with findings where NUAK2 enhances TGF␤ signaling in hepatocytes infected with hepatitis C virus, thus promoting liver fibrosis (18) . The regulation of CAGA 12 -luc reporter transcriptional activity by NUAK1 and NUAK2 (Fig. 6 , F and G) strongly suggests that these two protein kinases regulate the function of the SMAD3/SMAD4 complex, either in a direct manner (e.g. based on the association of NUAK2 with SMAD3) or indirectly via regulation of enzymes that control the stability and activity of nuclear SMADs (2).
As expected from the above impact of NUAK1 and NUAK2 on TGF␤ signaling, these two protein kinases regulate TGF␤induced cytostasis, EMT, myofibroblast differentiation, and contractility and suppression of myoblast differentiation (Figs. 7 and 8). NUAK1 and NUAK2 appear as proteins that "sense" the differentiation state of fibroblasts and mediate important functions during the myofibroblast switch. Such functions may involve the established phosphorylation and regulation of proteins of the myosin light chain system (17, 23) . However, the multiple responses to TGF␤ in epithelial and mesenchymal cells, some positive (EMT and myofibroblast differentiation) and some negative (e.g. suppression of epithelial cell cycle and of myocyte differentiation), suggest that the NUAKs may direct their activity toward the TGF␤ pathway, independent of biological context. A prediction worth testing is that elimination of both NUAK1 and NUAK2 simultaneously might result in neutral effects on TGF␤ signaling.
In vivo functions of Nuak1 and Nuak2 have been analyzed in mice. Nuak1 knockout leads to embryonic lethality due to defects in ventral body wall closure, whereas Nuak2 knockout causes partial exencephaly (38) . Double-knockout mutant mice generate facial clefting, spina bifida, and a stronger exencephaly (relative to single Nuak2 knockout) phenotypes (38) . Facial clefting resembles a phenotype revealed in the TGF␤3 knockout mouse, which may be compatible with a positive role of Nuak2 downstream of TGF␤ signaling, as demonstrated in this paper. Nuak1 can phosphorylate and stabilize Tau in neurons 
and, thus, contributes to regenerative deterioration of the brain in mice (39) . The heterozygous Nuak1 knockout/WT mouse exhibits haploinsufficiency that partially rescues neuronal deterioration caused by Tau accumulation (39) . Because TGF␤ signaling protects from brain degeneration, it is possible that the negative impact that NUAK1 has on TGF␤ signaling may reflect a mechanism of progressive deterioration of TGF␤ actions during neurodegeneration. Furthermore, the NUAKs are implicated in muscle homeostasis in vivo but do not show overt defects of muscle differentiation when knocked out in mice (16, 40) . Our evidence suggests involvement of the two NUAKs in C2C12 myoblast differentiation and its inhibition by TGF␤ (Fig. S3 ). Whether suppression of insulin signaling and glucose uptake in Nuak1-mutant muscle (40) or positive regulation of myocyte survival and muscle mass maintenance during aging by Nuak2 (16) reflect processes controlled by TGF␤ signaling, among other key pathways, remains to be examined.
We propose that the balance between the seemingly opposite roles of NUAK1 and NUAK2 on TGF␤ signaling can play important roles in epithelial and mesenchymal cell physiology. The spectrum of actions of NUAK1 and NUAK2 may range from the control of gene expression to the regulation of the cell cycle and cell differentiation, important cellular properties that define adult tissue homeostasis and diseases, such as tissue fibrosis and cancer.
Experimental procedures
Cell culture, transfections, and adenoviral infections
All original cell lines were obtained from ATCC (Manassas, VA). Mouse mammary epithelial NMuMG cells and their clone 18 (41) and NMuMG-Fucci (7, 9) , mouse C2C12 pluripotent cells, immortalized human keratinocytes HaCaT, primary human skin fibroblasts AG1523 used up to passage 20, cervical carcinoma HeLa cells, human lung adenocarcinoma A549 cells, human breast carcinoma MDA-MB-468 cells, and human embryonic kidney 293T cells were grown in DMEM containing 10% (or 15% in the case of C2C12) fetal bovine serum (FBS) (Biowest, Biotech-IgG AB, Lund, Sweden), penicillin and streptomycin, and 5 mM L-glutamine. Immortalized normal human mammary epithelial cells MCF10A and their Ras-transformed premalignant MCF10AneoT (MII) derivatives were cultured in DMEM/F-12 (Gibco, Life Technologies Europe BV, Stockholm, Sweden) supplemented with 5% horse serum (Biowest, Biotech-IgG AB, Lund, Sweden), 100 ng/ml cholera toxin (Sigma-Aldrich Sweden AB, Stockholm, Sweden), 20 ng/ml epidermal growth factor (Upstate, Millipore AB, Solna, Sweden), 0.5 g/ml hydrocortisone (Sigma-Aldrich Sweden AB), and 10 g/ml insulin (Sigma-Aldrich Sweden AB). Cells were maintained at 5% CO 2 in a humidified atmosphere at 37°C. TGF␤1 (PeproTech EC Ltd. Nordic (Stockholm, Sweden) and BIOSOURCE Inc. (Dacula, GA)), abbreviated as TGF␤, was used at concentrations as indicated in each experiment, spanning from 1 to 5 ng/ml. Scrambled (D-001810-10-50), hsNUAK1 (LU-004931-01), hsNUAK2 (L-005374-00), hsSMAD4 (L-003902-00) SMARTpool siRNAs, individual hsNUAK1 nr 2 (J-004931-10), hsNUAK1 nr 4 (J-004931-12), hsNUAK2 nr 2 (J-005374-09), and hsNUAK2 nr 4 (J-005374-11) were used. All siRNAs were purchased from Dharmacon (Thermo Fisher Scientific, Gothenburg, Sweden) and were transiently transfected twice on two consecutive days at 20 nM each, using Silentfect (Bio-Rad Laboratories AB, Sundbyberg, Sweden), into cells cultured in 5% FBS/DMEM in the absence of antibiotics, 72 h prior to TGF␤ stimulation. Single transfection of 100 nM mmNuak2 (L-051199-00), mmSmad4 (L-040687-00), or nontargeting (D-001810-10) ON-TARGETplus SMART pool siRNAs from Dharmacon (Thermo Fisher Scientific) was performed in NMuMG clone 18 cells. Individual mmNuak1 nr 3 (J-063024-07), mmNuak2 nr 1 (J-051199-05), and mmNuak2 nr 3 (J-051199-07) siRNAs, also from Dharmacon (Thermo Fisher Scientific), were transiently transfected into subconfluent C2C12 cell cultures on two consecutive days, at a final concentration of 50 nM each time, in DMEM plus 5% FBS. Two days after the first transfection, differentiation medium (DMEM plus 2% horse serum) was added in the presence or absence of TGF␤ (5 ng/ml) for 3 days. Then fresh medium was added for additional 3 days (6 days in total). Luciferase constructs were transfected into HEK 293T cells using Fugene HD (Roche AB, Solna, Sweden) according to the manufacturer's instructions.
For co-immunoprecipitation experiments, mammalian pcDNA3 empty vector or pcDNA3-FLAG-tagged SMAD2, SMAD3, or SMAD4; pcDNA3-6myc-tagged domains of SMAD3 (MH1, MH2, linker (L), full-length (FL), MH1ϩL, and LϩMH2); or pcDNA3-6myc-tagged empty vector have already been described (42, 43) . Human NUAK2 cDNA was cloned in the pEBG2t vector as a 2-kbp insert in Spe1-Spe1 restriction sites giving rise to GST-tagged NUAK2 and was provided by James C. Hastie (London, UK). All of the constructs with their corresponding controls were co-transfected to HEK 293T cells as 0.5 g of plasmid DNA, unless stated otherwise, by using Fugene HD (Roche AB), following the manufacturer's instructions.
Adenoviruses expressing ␤-gal (Adex-lacZ) and human SMAD4 (Adex-SMAD4) have been described previously (44) . Briefly, subconfluent MDA-MB-468 cells were trypsinized, A and B , AG1523 cells were subjected to double transfection with negative control or siRNA targeting NUAK1 (A) or NUAK2 (B) and treated with TGF␤ (1 ng/ml) for 24 h. Samples were subjected to immunoblotting for NUAK1, ␣SMA, calponin, and ␣-tubulin, which serves as a loading control (A), or for NUAK2, ␣SMA, calponin, SMAD3, and SMAD4, with Ponceau-S staining included as a loading control (B). A star shows nonspecific protein bands. Molecular size markers in kDa are shown. C, ␣SMA immunofluorescence microscopy of AG1523 cells after NUAK1, NUAK2, or negative control siRNA transfection using individual and distinct siRNAs. Cells were starved in 0.01% FBS/DMEM and incubated with TGF␤ (1 ng/ml) as indicated. Representative photomicrographs are shown. Bar, 20 m. D, collagen gel contraction assay with AG1523 cells transfected with control or individual and distinct NUAK1 siRNAs (left panels) or individual and distinct NUAK2 siRNAs (right panels). Two days after the first transfection, TGF␤ (5 ng/ml in 0.01% FBS/DMEM) was added, and the contracted lattice surface was measured 24 h post-treatment. Surface area was measured by using the ImageJ software and is illustrated in the corresponding graphs. Representative pictures of contracted lattices are shown. Bar graphs show average values derived from triplicate determinations and the corresponding S.E. (error bars). Each independent experiment was repeated at least three times. E, mRNA levels of calponin, ACTA2, and SM22␣ from the samples used in C and D. After performing real-time qRT-PCR, values were normalized to HPRT1 mRNA. Asterisks illustrate significant differences between the conditions indicated and respective control: *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001.
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counted, and reseeded in 0.01% FBS-containing medium in 24-well plates at a concentration of 60,000 cells/well and used in triplicates per condition. While still in suspension, adenoviral constructs were added to the medium. Twenty-four hours postinfection, cells were treated with TGF␤ for the time periods indicated in the figures, and protein expression or luciferase activity was measured as described below.
Antibodies and chemicals
Anti-NUAK2 antibody was purchased from Sigma-Aldrich Sweden AB; anti-phosho(Ser-465/Ser-467)-SMAD2 antibody was homemade; anti-SMAD2 antibody was from Epitomics, Cell Marque/Sigma-Aldrich Sweden; anti-␣-tubulin, anti-␤actin, anti-GST, anti-Myc, and anti-T␤RI V22 were from Santa Cruz Biotechnology Inc. (Dallas, TX); anti-SMAD2/3 antibody and anti-PAI-1 (plasminogen activator inhibitor 1) were from BD Bioscience AB, Stockholm, Sweden; anti-NUAK1, antiphospho-SMAD3, anti-SMAD3, anti-SMAD4, anti-phospho-p44/42 MAPK (ERK1/2-Thr 202 /Tyr 204 ), and anti-Snail (catalog no. 3789) antibodies were from Cell Signaling Technology (Leiden, The Netherlands); anti-myosin heavy chain antibody clone A4.1025 and anti-myogenin were from Merck/Millipore (Darmstadt, Germany).
Cycloheximide (Sigma-Aldrich Sweden AB) was used at a concentration of 40 g/ml, and actinomycin D (Sigma-Aldrich Sweden AB) was used at 4 g/ml. T␤RI kinase inhibitor GW6604 was used at a final concentration of 3 M and was synthesized by the Ludwig Cancer Research Ltd. T␤RI kinase inhibitor LY2157299 (Cayman Chemical Co., Stockholm, Sweden) was used at a final concentration of 5 M, whereas T␤RI kinase inhibitor SB505124 (Sigma-Aldrich Sweden AB) was applied at a concentration of 2.5 M. MEK kinase inhibitor Cl-1040 (PD184352), used at 0.5 M, and p38 MAPK inhibitor SB203580, used at 10 M, were from Calbiochem, Merck (Darmstadt, Germany). Chemical inhibitors or DMSO (vehicle) were added to cells starved overnight, 1 h prior to TGF␤ stimulation.
Immunoblotting and co-immunoprecipitation
Cells were lysed in radioimmune precipitation assay buffer containing 50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, supplemented with complete protease inhibitor mixture (Roche Diagnostics, Bromma, Sweden) and phosphatase inhibitors (1 mM sodium orthovanadate, 50 mM sodium fluoride), incubated for 30 min on ice including occasional vortexing, centrifuged at 13,000 rpm, and boiled in sample buffer containing 5% ␤-mercaptoethanol as a reducing agent and 2% SDS as a denaturing agent. Samples were subjected to SDS-PAGE, followed by wet transfer to nitrocellulose membranes (Amersham Biosciences Protran 0.45 NC, GE Healthcare, Uppsala, Sweden) and blocking (5% BSA in Trisbuffered saline, 0.1% Tween 20) for 1 h at room temperature. Primary antibodies were incubated overnight at 4°C. Secondary antibodies were incubated for 1 h at room temperature before detection with chemiluminescence substrate (Santa Cruz Biotechnology) and X-ray films (Fujifilm Nordic AB, Stockholm, Sweden).
For co-immunoprecipitation assays, cells were lysed in a buffer consisting of 0.5% Triton X-100, 11.5 mM sodium deoxycholate, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, and complete protease inhibitor mixture from Roche Diagnostics for 30 min on ice; the cell pellet was removed after centrifugation at 13,000 rpm for 15 min at 4°C. Cell lysates were precleared for 1 h with 10 l of protein A Dynabeads end-over-end. Subsequently, they were incubated with mouse anti-FLAG-M2 F-3165 (Sigma-Aldrich Sweden AB) or anti-Myc (Thermo Fisher Scientific) embedded agarose beads (30-l final volume PBS/slurry, 1:1) for 1 h at 4°C. For semi-endogenous immunoprecipitations, 3 g of anti-T␤RI V22 or normal anti-rabbit IgG (ab46540, Abcam, Cambridge, UK) were used, and for SMAD3 co-immunoprecipitations, 3 g of specific antibody (ab28379, Abcam) or an equivalent amount of anti-rabbit IgG as a negative control were used. On the next day, 30 l of protein A Dynabeads were added to the lysates for 1 h at 4°C. After five washes with lysis buffer, the immunocomplexes were resolved by SDS-PAGE and immunoblotted with antibodies, as described in the figure legends.
Chromatin immunoprecipitation (ChIP)
NMuMG cells were grown to 80 -90% confluence in 15-cm plates and stimulated with 5 ng/ml TGF␤ for 1 h, prior to crosslinking with 1% formaldehyde via incubation on a shaking platform for 10 min at room temperature. Cross-linked cells were washed with ice-cold PBS, and cell pellets were resuspended in 1.5 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS, supplemented with protease inhibitor mixture (Roche Diagnostics)). Total cell lysate was sonicated in a water-bath Diagenode Bioraptor sonicator with 30-s pulses for 15 min at high frequency to obtain short DNA fragments. The lysate was subsequently centrifuged at 14,000 rpm in 4°C for 10 min. ChIP was performed overnight at 4°C with 10 g of mouse monoclonal anti-SMAD2/3 (BD Bioscience AB) or 10 g of nonspecific preimmune mouse immunoglobulin (homemade), together with magnetic beads (Dynabeads M280, Invitrogen, Thermo Fisher Scientific) and dilution buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1% Triton X-100, 150 mM NaCl, and protease inhibitor mixture (Roche Diagnostics) in a total volume of 15 ml (sonicated cell lysate was diluted 1:10). The precipitated complexes were washed five times with radioimmune precipitation assay washing buffer (50 mM HEPES-KOH, pH 7.0, 0.5 M LiCl, 1 mM EDTA, 0.7% (w/v) sodium deoxycholate, 1% Igepal CA630) and once with TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and DNA was eluted in 200 l of elution buffer (lysis buffer without protease inhibitor mixture) after shaking at 65°C for 6 h. For the ChIP input controls, 100 l of sonicated cell lysate were diluted 4 times with elution buffer and treated at 65°C for 6 h. Eluted DNA and input DNA were purified using a PCR purification kit (Qiagen AB, Sollentuna, Sweden) and were then analyzed by a qPCR assay using specific primers for the mouse Nuak2 intron-enhancer region (forward, 5Ј-TGAG-AAACGACGGAGACAAGCTGCT-3Ј; reverse, 5Ј-GTCTGG-AGGTTTTGCTGCAGGTCTG-3Ј), mouse Pai-1 enhancer (forward, 5Ј-GTCCAAGAGGAACGAGAACC-3Ј; reverse, 5Ј-GGCTTTGTAGGCTCTTGTGG-3Ј), and mouse Hbb (hemoglobin B) gene serving as a control genomic region (forward,
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5Ј-CAACCTGCCCAGGGCCTCAC-3Ј; reverse, 5Ј-AGGCT-GCTGTCTCTGGCCTGT-3Ј). The qPCR protocol was as follows: 95°C for 5 min, followed by 39 cycles of 95°C for 15 s and 60°C for 1 min.
Promoter cloning and luciferase-reporter constructs
The mouse Nuak2 promoter and enhancer sequences were amplified from genomic DNA isolated from mouse NMuMG cells using primers mapping upstream and downstream of the TSS and upstream and downstream of the intronic enhancer element, which was first identified in a genome-wide screen for SMAD2/3 binding in human epithelial cells (32) . For the amplification of the 2-kbp promoter fragment, the primers used were 5Ј-AGTAGTTGGTGACTGGGTGCAAGGG-3Ј (forward) and 5Ј-GAGTGGGTCGGGCAGCAGTAGCA-3Ј (reverse). For the 1-kbp promoter fragment, the primers were 5Ј-AGTCCTCTTT-GATCCTCTGCCAAGTCC-3Ј (forward) and 5Ј-GAGTGGGT-CGGGCAGCAGTAGCA-3Ј (reverse). For the amplification of the intronic enhancer fragment, the primers used were 5Ј-GCTC-CCCTGACCAACCCCTAAAGAG-3Ј (forward) and 5Ј-CTGG-AGCTAGCCGATGGGATGACAA-3Ј (reverse). The amplified promoter sequences were cloned into vector pGL4.12 (Promega Corp., Madison, WI) and the enhancer sequence into vector pGL4.24 (Promega Corp., Madison, WI) in one step; the PCRamplified genomic DNA fragments were blunt-end ligated into the pGL4.12 and pGL4.24 vectors after cutting with EcoRV, producing pGL4.12-mNuak2P-1kbp and pGL4.12-mNuak2P-2kbp (carrying the mouse Nuak2 promoters only) and pGL4.24-mNuak2/intron (carrying the mouse Nuak2 enhancer of intron 1). The cloned promoter fragments correspond to 1,102 and 2,274 bp spanning from Ϫ1,030 and Ϫ2,202 to ϩ63 bp relative to the TSS of the mouse Nuak2 gene, respectively (Fig. 3A) . The cloned enhancer fragment corresponds to 420 bp spanning from ϩ2,374 to ϩ2,794 bp relative to the TSS, and the sequence is located in the first intronic region of the Nuak2 gene (Fig. 3A) . All Nuak2 gene bp coordinates are given based on the ENSEMBL NCBIM37 version of the mouse genome. pEGFP-N3 (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) was used for normalization of promoter assays.
Luciferase assays
HEK 293T and NMuMG cells were transiently transfected with the Nuak2 promoter/enhancer reporter constructs for 36 h prior to stimulation with 5 ng/ml TGF␤ for 18 h. pEGFP-N3 (Takara Bio Europe/Clontech) was transfected as control for normalization. The T␤RI ALK5 (activin receptorlike kinase 5) mutant pcDNA3-HA-ALK5TD that signals in a constitutive manner has been described previously (7) and was transfected to provide a sustained stimulus of endogenous TGF␤ signaling. The pCAGA 12 -MLP-luc reporter and pCMV-␤-gal used for normalization were described (43) . Transfected cells were lysed in lysis buffer containing 5 mM Tris-phosphate buffer, pH 7.8, 2 mM DTT, 2 mM trans-1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid, 5% glycerol, and 1% Triton X-100. The ␤-gal assay was performed by mixing the cell lysate with 100 mM sodium phosphate, pH 7.3, 1 mM MgCl 2 , 50 mM ␤-mercaptoethanol, and 0.67 mg/ml 2-nitrophenyl ␤-Dgalactopyranoside, and the absorbance was monitored at 420 nm. Luciferase reporter assays were performed with the firefly luciferase assay kit from Biotium (Fremont CA) (BTIU30003-2), according to the protocol of the manufacturer. Normalized promoter activity is plotted in bar graphs that represent average values from triplicate determinations with S.D. values.
Real-time PCR analysis and primers
Total RNA was extracted using RNeasy (Qiagen AB), and cDNA synthesis using a reverse transcription kit (Bio-Rad Laboratories AB) was followed by PCR amplification with the primers indicated in Table 1 , as described previously (7, 9) .
Thymidine incorporation assay
HaCaT and NMuMG cells were seeded in subconfluent conditions in 12-well plates and subsequently were subjected to either NUAK1 or Nuak2 knockdown, respectively, according to the aforementioned standard siRNA transfection protocol. Twenty-four hours after the second transfection, cells were treated with medium containing 2% FBS in the presence or absence of TGF␤ at a final concentration of 5 ng/ml for 24 h, and for the last 6 h, the medium in each well was supplemented with [ 3 H]thymidine at a final concentration of 1 Ci/ml. Following wash in ice-cold PBS and fixation with 5% TCA, cells were lysed in 0.1 M NaOH, and the incorporated [ 3 H]thymidine was measured by scintillation counting. Every individual experiment was performed in triplicate.
Living cell analysis of the cell cycle
NMuMG-Fucci cells were transiently transfected with siRNAs twice and stimulated with TGF␤ for 24 h as described above. Then fluorescence microscopy and image analysis were performed as described previously (7, 9) .
Collagen gel contraction assay
Three hundred thousand AG1523 cells were seeded in p60 dishes and were transfected according to the standard siRNA transfection protocol described earlier. Following the double transfection, cells were starved overnight with medium containing 0.01% FBS. During the same day, 12-well culture dishes were coated with freshly produced filtered 1% IgG-free BSA in PBS and incubated overnight at 37°C to block the surface of the dishes, preventing attachment of the newly formed collagen gel. On the next day, AG1523 cells were trypsinized, counted, and seeded into a 1 mg/ml type I collagen solution (PureCol, Advanced BioMatrix Inc., Carlsbad, CA) in ice-cold DMEM at a concentration of 50,000 cells/ml/well. Triplicates were used per condition. After homogenizing the mixture by gentle pipetting, 1 ml of the collagen/cell suspension was added to the BSA-coated dishes, and the solution was incubated for 45 min at 37°C until the gel was polymerized. Fresh medium containing the indicated treatment conditions was used to supplement the solidified collagen gels, and the contracted surface area was monitored up to 48 h and calculated by employing the ImageJ software.
Immunofluorescence microscopy
Immunofluorescence microscopy was carried out in NMuMG and AG1523 cells after the indicated siRNA transfection condi-
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tions. Following the stated treatments, cells were fixed in 6-well plates for 12 min in 3.7% (w/v) formaldehyde in PBS, followed by permeabilization with 0.1% Triton X-100 in PBS for 10 min, blocked for 60 min with IgG-free 1% BSA in PBS, and incubated overnight at 4°C with the indicated primary antibodies against ␣SMA (1:200) (Santa Cruz Biotechnology, sc-32251), fibronectin (1:1,000) (Sigma-Aldrich, F3648), ZO-1 (1:200) (Life Technologies (Stockholm, Sweden), 33-9100) all diluted in 1% BSA/PBS. Following primary antibody incubation, the fixed-permeabilized cells were incubated with anti-mouse or anti-rabbit Alexa Fluor 488or Alexa Fluor 546 -conjugated secondary antibodies (Invitrogen, Thermo Fisher Scientific) at a concentration of 1:1,000 in 1% BSA/ PBS for 1 h at room temperature in the dark. Extensive washes were performed between the aforementioned steps. Subsequently, coverslips were set onto glass slides and mounted by using 10 l of VectaShield HardSet mounting medium containing 4Ј,6Ј-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) for nuclear visualization. A Zeiss Axioplan 2 fluorescence microscope was used with the Zeiss 40ϫ objective lens. Images were acquired with a Hamamatsu C4742-95 CCD digital camera and the acquisition software QED Camera Plugin version 1.1.6 (QED Imaging Inc., Rockville, MD) and Volocity 1 (PerkinElmer Life Sciences).
Statistical analysis
Graphs illustrate mean Ϯ S.E. and are based on at least three independent biological experiments, unless stated otherwise. Two-paired Student's t test was used to calculate significance; three significance levels are indicated (*, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001). 
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